3320.HK WACC - Weighted Average Cost of Capital

The WACC of China Resources Pharmaceutical Group Ltd (3320.HK) is 7.0%.

The Cost of Equity of China Resources Pharmaceutical Group Ltd (3320.HK) is 14.85%.

The Cost of Debt of China Resources Pharmaceutical Group Ltd (3320.HK) is 4.25%.

	Range	Selected
Cost of equity	12.50% - 17.20%	14.85%
Tax rate	21.20% - 22.00%	21.60%
Cost of debt	4.00% - 4.50%	4.25%
WACC	6.1% - 7.8%	7.0%

WACC

3320.HK WACC calculation

Category	Low	High

Long-term bond rate	2.9%	3.4%
Equity market risk premium	6.0%	7.0%
Adjusted beta	1.6	1.91

Additional risk adjustments	0.0%	0.5%
Cost of equity	12.50%	17.20%

Tax rate	21.20%	22.00%
Debt/Equity ratio	2.16	2.16
Cost of debt	4.00%	4.50%

After-tax WACC	6.1%	7.8%


Selected WACC	7.0%

3320.HK's CAPM model and how its cost of Equity is calculated

The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.

This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.

Here’s how we figure out the cost of equity for 3320.HK:

cost_of_equity (14.85%) = risk_free_rate (3.15%) + equity_risk_premium (6.50%) * adjusted_beta (1.6) + risk_adjustments (0.25%)

We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.